Hepatic Disease

Licogliflozin, a SGLT-1/2 Inhibitor, Shows Potential for Treatment of NASH
June 22, 2022

The sodium-glucose cotransporter 1/2 inhibitor at 150 mg was associated with a significant 32% reduction in liver enzyme levels in a phase 2a clinical trial.

Nonalcoholic Fatty Liver Disease: A 7-question Quiz for Primary Care Clinicians
June 15, 2022

How prevalent is NAFLD worldwide? What is the preferred treatment? And more questions to test your NAFLD knowledge.